Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials
finance.yahoo.com
27.08.2026 14:43
2 baxış
Əlaqəli xəbərlər
Bath & Body Works Q2 net sales fall amid weak underlying demand
finance.yahoo.com · 27.08
Earnings spur software and chip rally, offsetting weakness in other areas of the market: AlphaCheck
finance.yahoo.com · 27.08
Nasdaq rises as Nvidia stock jumps on revenue forecast
finance.yahoo.com · 27.08
3 High-Yield Dividend Stocks Near Their 52-Week Lows That Income Investors Are Sleeping On
finance.yahoo.com · 27.08
Delivery Hero raises full-year 2026 guidance after strong H1
finance.yahoo.com · 27.08
Palo Alto Networks’ CEO Says Nebius Is in a Different League. Is This ‘Neoscaler’ a Buy?
finance.yahoo.com · 27.08